Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Top Cited Papers
- 10 July 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (20), 3239-3247
- https://doi.org/10.1200/jco.2008.21.6457
Abstract
Purpose The efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) –negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial. Patients and Methods Patients (N = 736) were randomly assigned to docetaxel 100 mg/m2 plus either placebo or bevacizumab 7.5 or 15 mg/kg every 3 weeks. The primary end point was progression-free survival (PFS); secondary end points included best overall response, duration of response, time to treatment failure, overall survival, and safety. Results Combination of bevacizumab 15 mg/kg, but not 7.5 mg/kg, with docetaxel showed superior median PFS (mPFS) to placebo plus docetaxel in unstratified analysis (placebo mPFS, 8.2 months; 7.5 mg/kg mPFS, 9.0 months [hazard ratio (HR), 0.86; P = .12]; 15 mg/kg mPFS, 10.1 months [HR, 0.77; P = .006]) and stratified analysis (placebo mPFS, 8.1 months; 7.5 mg/kg mPFS, 9.0 month...This publication has 20 references indexed in Scilit:
- VEGF-targeted therapy: mechanisms of anti-tumour activityNature Reviews Cancer, 2008
- The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumabEuropean Journal Of Cancer, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerThe New England Journal of Medicine, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2006
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerThe New England Journal of Medicine, 2004
- Prognostic Significance of Vascular Endothelial Growth Factor Protein in Node-Negative Breast CarcinomaJNCI Journal of the National Cancer Institute, 1997
- Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancerHuman Pathology, 1995
- Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expressionBreast Cancer Research and Treatment, 1995
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971